Business
Paramount Skydance To Reportedly Make Bid For Warner Bros. Discovery
(Mario Tama/Getty Images)

Opponents of the Netflix-Warner Bros. deal take fight to Europe

Europe is the latest frontier of the ongoing tug-of-war for the “Friends” back catalog.

Struggling to gain a foothold in the US, the groups opposing Netflix’s $83 billion acquisition of Warner Bros. Discovery are mounting a European assault.

Paramount Skydance CEO David Ellison this week met with top European film industry execs and French President Emmanuel Macron in Paris, while other Paramount execs traveled to the UK and Germany to lobby regulators against Netflix’s offer.

Trade groups representing AMC and other movie theaters with European exposure also lobbied EU regulators against Netflix’s deal.

The efforts come as Netflix racks up small US wins in its war of attrition to complete the deal. A Delaware judge on Thursday dismissed Paramount’s motion to speed up its lawsuit against WBD. Paramount’s current $30-per-share offer expires on January 21, though Warner Bros. argued that Paramount “set its own expiration date.”

On Friday, Netflix appeared to dispel theater owners’ fears about limited release windows, with co-CEO Ted Sarandos telling The New York Times that the company would run Warner Bros.’ film business largely like it’s run today.

“When this deal closes, we will own a theatrical distribution engine that is phenomenal and produces billions of dollars of theatrical revenue that we don’t want to put at risk. We will run that business largely like it is today, with 45-day windows,” Sarandos said. Shares of AMC and Imax climbed on Friday following the interview.

Those moves follow reports earlier this week that Netflix is planning to strengthen its current WBD offer by making it all-cash.

Event contracts are beginning to swing heavily in Netflix’s favor, with Paramount’s odds to end up in control of WBD falling to 19% as of 11:30 a.m. ET on Friday, down from 31% on Thursday.

(Event contracts are offered through Robinhood Derivatives, LLC — probabilities referenced or sourced from KalshiEx LLC or ForecastEx LLC.)

More Business

See all Business
business

Ford reportedly in talks to buy hybrid vehicle batteries from Chinese auto giant BYD

Detroit’s Ford and China’s BYD are said to be in ongoing talks to partner on an agreement that would see Ford buy hybrid vehicle batteries from BYD, according to reporting from The Wall Street Journal.

The report comes just days after President Trump toured a Ford factory in Michigan and implied openness to Chinese automakers coming to the US.

“If they want to come in and build a plant... that’s great, I love that,” Trump said on January 13. “Let China come in, let Japan come in.”

Last week, China’s Geely Automobile Holdings said it expects to make an announcement about expanding into the US within the next three years. Chinese carmakers currently face huge tariffs and software restrictions, effectively barring their vehicles from the US.

Ford has doubled down on hybrid vehicles amid high EV costs and the end of federal EV tax credits. The automaker is currently building a battery plant in Michigan where it plans to use tech from Chinese battery maker CATL.

“If they want to come in and build a plant... that’s great, I love that,” Trump said on January 13. “Let China come in, let Japan come in.”

Last week, China’s Geely Automobile Holdings said it expects to make an announcement about expanding into the US within the next three years. Chinese carmakers currently face huge tariffs and software restrictions, effectively barring their vehicles from the US.

Ford has doubled down on hybrid vehicles amid high EV costs and the end of federal EV tax credits. The automaker is currently building a battery plant in Michigan where it plans to use tech from Chinese battery maker CATL.

Still life of Ozempic and Wegovy with weight scale.

Lawsuit alleges Lilly, Novo locked up telehealth to kill compounded GLP-1s

Novo Nordisk CEO Mike Doustdar estimated that around 1.5 million US patients are using compounded versions of the company’s drugs.

Handshake

Big Pharma enters 2026 with an appetite for deals

At the JPMorgan Healthcare Conference, biotechs and Big Pharma signaled they’re primed for M&A this year, after a big year for deals in 2025.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.